NL191540B - Compound with anti-hypercholesteremic activity, as well as a pharmaceutical composition containing this compound. - Google Patents

Compound with anti-hypercholesteremic activity, as well as a pharmaceutical composition containing this compound.

Info

Publication number
NL191540B
NL191540B NL8001041A NL8001041A NL191540B NL 191540 B NL191540 B NL 191540B NL 8001041 A NL8001041 A NL 8001041A NL 8001041 A NL8001041 A NL 8001041A NL 191540 B NL191540 B NL 191540B
Authority
NL
Netherlands
Prior art keywords
compound
hypercholesteremic
activity
well
pharmaceutical composition
Prior art date
Application number
NL8001041A
Other languages
Dutch (nl)
Other versions
NL191540C (en
NL8001041A (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NL8001041A publication Critical patent/NL8001041A/en
Publication of NL191540B publication Critical patent/NL191540B/en
Application granted granted Critical
Publication of NL191540C publication Critical patent/NL191540C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL8001041A 1979-02-20 1980-02-20 Compound with anti-hypercholesteremic activity, as well as a pharmaceutical composition containing this compound. NL191540C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1785679 1979-02-20
JP54017856A JPS5925599B2 (en) 1979-02-20 1979-02-20 New physiologically active substance monacolin K and its production method

Publications (3)

Publication Number Publication Date
NL8001041A NL8001041A (en) 1980-08-22
NL191540B true NL191540B (en) 1995-05-01
NL191540C NL191540C (en) 1995-09-04

Family

ID=11955290

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8001041A NL191540C (en) 1979-02-20 1980-02-20 Compound with anti-hypercholesteremic activity, as well as a pharmaceutical composition containing this compound.

Country Status (27)

Country Link
JP (1) JPS5925599B2 (en)
KR (1) KR830002801B1 (en)
AT (1) AT373915B (en)
AU (1) AU532626B2 (en)
BE (1) BE881825A (en)
CA (1) CA1129794A (en)
CH (1) CH645890A5 (en)
DD (1) DD154494A5 (en)
DE (2) DE3006216C2 (en)
DK (2) DK149095C (en)
ES (1) ES488796A0 (en)
FI (1) FI66427C (en)
FR (1) FR2449685B1 (en)
GB (1) GB2046737B (en)
HU (1) HU182069B (en)
IE (1) IE49743B1 (en)
IT (1) IT1175260B (en)
MX (1) MX6314E (en)
NL (1) NL191540C (en)
NO (1) NO153974C (en)
NZ (1) NZ192919A (en)
PH (1) PH15145A (en)
PL (1) PL124304B1 (en)
SE (1) SE453301B (en)
SG (1) SG6784G (en)
SU (2) SU1158048A3 (en)
ZA (1) ZA80962B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS5621594A (en) * 1979-07-27 1981-02-28 Sankyo Co Ltd Mb-530b carboxylic acid metal salt and its preparation
PT72394B (en) * 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
JPH0692381B2 (en) * 1980-03-31 1994-11-16 三共株式会社 MB-530A derivative
JPS56142236A (en) 1980-04-08 1981-11-06 Sankyo Co Ltd Ml-236a and mb-530a derivative
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
JPS5835144A (en) * 1981-08-27 1983-03-01 Sankyo Co Ltd Mb-530b derivative and its preparation
US4782084A (en) * 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
CA2062023A1 (en) 1992-02-10 1993-08-11 Jagroop S. Dahiya Novel fungal strains and use thereof in antibiotic production
EP0629184A1 (en) * 1992-03-04 1994-12-21 Fujisawa Pharmaceutical Co., Ltd. TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS
ZA933359B (en) 1992-05-15 1993-12-08 Sankyo Co Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use
US6812007B1 (en) * 1992-11-04 2004-11-02 Keri Vilmos Process for the isolation and purification of mevinolin
HU210867B (en) * 1992-11-04 1995-10-30 Biogal Gyogyszergyar Method for extraction and purification of mevinolin from culture medium
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
US5409820A (en) * 1993-08-06 1995-04-25 Apotex, Inc. Process for the production of lovastatin using Coniothyrium fuckelii
US6046022A (en) 1996-09-30 2000-04-04 Peking University Methods and compositions employing red rice fermentation products
US7238348B2 (en) 1996-09-30 2007-07-03 Beijing Peking University Wbl Corporation Ltd. Method of treatment of osteoporosis with compositions of red rice fermentation products
CZ300153B6 (en) 1998-03-20 2009-02-25 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Metabolically controlled fermentation process when preparing lovastatin hydroxy acid
AU3654301A (en) 2000-02-24 2001-09-03 Biogal Gyogyszergyar Method of purifying a fermentation broth
JP2003525935A (en) 2000-03-03 2003-09-02 ビオガル ジョジセルジャール アール テー． Method for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
KR20010095780A (en) * 2000-04-12 2001-11-07 나가오카 마사시 Embryo monascus
IN192861B (en) 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
AU2002235885A1 (en) 2001-02-09 2002-08-28 Unilever N.V. Process for the preparation of one or more statins by fermentation
KR100379075B1 (en) 2002-03-07 2003-04-08 Jinis Biopharmaceuticals Co Method for producing low cholesterol animal food product and food product therefrom
KR20020093147A (en) * 2002-05-30 2002-12-13 지니스생명공학 주식회사 Preventive and Dietary Supplement for adult chronic disease
KR100710500B1 (en) 2005-05-18 2007-04-24 고려대학교 산학협력단 Method for producing Monacolin K using Monascus sp
SI2373609T1 (en) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
RO128803A0 (en) 2012-10-12 2013-09-30 Ion Gigel Fulga Composition for the treatment or prevention of dyslipidemias
CN110331151A (en) * 2019-04-11 2019-10-15 北京工商大学 The construction method of purple Monascus mokH gene overexpression bacterial strain
CN111297938A (en) * 2020-03-11 2020-06-19 北京康立生医药技术开发有限公司 Method for detecting lovastatin in composition for assisting in reducing blood fat

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) * 1974-06-07 1981-03-18
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b
GR69216B (en) * 1979-06-15 1982-05-07 Merck & Co Inc

Also Published As

Publication number Publication date
KR830002030A (en) 1983-05-21
NO153974C (en) 1986-06-25
HU182069B (en) 1983-12-28
PL124304B1 (en) 1983-01-31
AU5567380A (en) 1980-08-28
PL222120A1 (en) 1980-10-20
SE8001339L (en) 1980-08-21
NO153974B (en) 1986-03-17
IE800321L (en) 1980-08-20
SG6784G (en) 1985-02-08
SU1158048A3 (en) 1985-05-23
DE3051175C2 (en) 1989-12-21
DE3006216C2 (en) 1985-10-31
DD154494A5 (en) 1982-03-24
CA1129794A (en) 1982-08-17
NZ192919A (en) 1984-07-06
AT373915B (en) 1984-03-12
DK21889A (en) 1989-01-18
ES8103171A1 (en) 1981-02-16
JPS55111790A (en) 1980-08-28
FI800506A (en) 1980-08-21
ZA80962B (en) 1981-03-25
IE49743B1 (en) 1985-12-11
CH645890A5 (en) 1984-10-31
GB2046737B (en) 1983-01-12
GB2046737A (en) 1980-11-19
IT8067262A0 (en) 1980-02-20
NL191540C (en) 1995-09-04
JPS5925599B2 (en) 1984-06-19
ATA92980A (en) 1983-07-15
FI66427B (en) 1984-06-29
AU532626B2 (en) 1983-10-06
BE881825A (en) 1980-08-20
IT1175260B (en) 1987-07-01
PH15145A (en) 1982-08-24
DK149095C (en) 1986-06-16
NL8001041A (en) 1980-08-22
MX6314E (en) 1985-04-01
NO800451L (en) 1980-08-21
FI66427C (en) 1984-10-10
FR2449685A1 (en) 1980-09-19
DK21889D0 (en) 1989-01-18
FR2449685B1 (en) 1985-06-28
ES488796A0 (en) 1981-02-16
KR830002801B1 (en) 1983-12-16
DE3006216A1 (en) 1980-09-04
SU969702A1 (en) 1982-10-30
DK149095B (en) 1986-01-20
DK73080A (en) 1980-08-21
SE453301B (en) 1988-01-25

Similar Documents

Publication Publication Date Title
NL191540C (en) Compound with anti-hypercholesteremic activity, as well as a pharmaceutical composition containing this compound.
NL193457B (en) Benzoheterocyclic compounds and pharmaceutical composition containing such a compound.
NL190553C (en) Substituted (2-imidazolin-2-yl) aminopirimidines, as well as a pharmaceutical composition with antihypertensive activity, containing one or more of these compounds.
NL7804974A (en) 2-PENEM-3-CARBONIC ACID COMPOUNDS.
NL190519C (en) 4-Substituted phenylacetic acid compounds, as well as pharmaceutical preparations.
NL7803721A (en) GUAJACONIC ACID A AND DIAGNOSTIC AGENT CONTAINING THIS COMPOUND.
IT8019817A0 (en) IMPROVED CATALYTIC COMPOSITION PREPARATION.
NL189561C (en) SUBSTITUTED CYCLO-ALKYLIDENE METHYLPHENYLACETIC ACID COMPOUNDS, AND A PHARMACEUTICAL PREPARATION CONTAINING THESE COMPOUNDS.
NL191306C (en) 4-quinolone derivative, as well as a drug containing this derivative.
NL190781C (en) N-acylphosphoric triamides, as well as drugs containing N-acylphosphoric triamides.
NL7805588A (en) 3,3,3-TRIARYLALKYL-4-PHENYLALKYL-4-HYDROXYPIPERIDINS WITH MEDICINAL ACTIVITY.
NL7811800A (en) LEAD PYROCHLORINE TYPE COMPOUNDS.
NL7812257A (en) COMPOUNDS WITH ANTICHOLINERGIC AND ANTISECRETORY ACTION, AS WELL AS PHARMACEUTICAL AND ANTITRAPIRATION PREPARATIONS CONTAINING SUCH A COMPOUND.
IT7926662A0 (en) PHARMACEUTICAL COMPOSITION CONTAINING 3,4-DI-HYDRO-3-OXO-2-QUINOXALINES.
DK147300C (en) 24,24-DIFLUOR-25-HYDROXY-6-ALCOXY-3,5-CYCLOVITAMINE D3 COMPOUNDS
NL191386C (en) A 16-hydroxy-prostaglandin compound.
ES508222A0 (en) "PROCEDURE, TO PREPARE DECA-, UNDECA- AND TRIDECAPEPTIDOS WITH TIMICA ACTIVITY".
NL193191B (en) 1,3-Oxazolidine-2-one derivatives and a pharmaceutical composition containing such a compound.
IT7925538A0 (en) N-ARIL-N-ACIL-3-AMINO-OXAZOLIDIN2-ONI FUNGICIDES.
NL191709C (en) C8-substituted ergoline derivatives as well as a drug comprising these derivatives.
IT8025577A0 (en) LONG-ACTING PHARMACEUTICAL COMPOSITION.
NL930014I2 (en) 2,4-Dichloro-alpha (N-imidazolylmethyl) -dibenzyl ether derivative and a pharmaceutical composition comprising this compound.
IT1209196B (en) CLINCHER IMPROVEMENTS.
NL7808946A (en) BETA SUBSTITUTED DIETONES, AS WELL AS PREPARATIONS CONTAINING THESE COMPOUNDS.
NL7610898A (en) SUBSTITUTED CEFEM CARBONIC ACID COMPOUNDS WITH ANTI-BACTERIAL ACTIVITY.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
A85 Still pending on 85-01-01
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 20000220